These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 20110000

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G, Wróbel T, Podolak-Dawidziak M, Kuliszkiewicz-Janus M, Potoczek S, Nosol J, Kuliczkowski K.
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [Abstract] [Full Text] [Related]

  • 3. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.
    N Engl J Med; 2005 Jul 07; 353(1):33-45. PubMed ID: 16000354
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun 07; 15(83):83-6. PubMed ID: 16764090
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M.
    Eur J Haematol; 2017 Feb 07; 98(2):106-111. PubMed ID: 27557754
    [Abstract] [Full Text] [Related]

  • 12. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ, FOX study investigators.
    Eur J Haematol; 2014 Feb 07; 92(2):127-36. PubMed ID: 24118452
    [Abstract] [Full Text] [Related]

  • 13. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR, Di Francesco E, Pezzella F, Tibullo D, Giustolisi R, Cacciola E.
    Acta Haematol; 2007 Feb 07; 118(4):215-8. PubMed ID: 18057866
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
    Ito T, Hashimoto Y, Tanaka Y, Nakaya A, Fujita S, Satake A, Nakanishi T, Konishi A, Hotta M, Yoshimura H, Ishii K, Hashimoto A, Kondo T, Omura H, Shinzato I, Tanaka T, Nomura S.
    Eur J Haematol; 2019 Aug 07; 103(2):116-123. PubMed ID: 31107982
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Samuelson B, Chai-Adisaksopha C, Garcia D.
    J Thromb Thrombolysis; 2015 Nov 07; 40(4):474-9. PubMed ID: 25894476
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.